

UNCLASSIFIED

AD 296 556

*Reproduced
by the*

**ARMED SERVICES TECHNICAL INFORMATION AGENCY
ARLINGTON HALL STATION
ARLINGTON 12, VIRGINIA**



UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

63-2-4

SAM-TDR-62-103

29 6556

AS AD NO.

PROTECTION AGAINST IONIZING RADIATION

X-irradiated Monkeys Receiving Preirradiation Prophylaxis and Postirradiation Therapy


296 556

TECHNICAL DOCUMENTARY REPORT NO. 62-103

December 1962

USAF School of Aerospace Medicine
Aerospace Medical Division (AFSC)
Brooks Air Force Base, Texas

Project No. 7757, Task No. 67007



Qualified requesters may obtain copies of this report from ASTIA. Orders will be expedited if placed through the librarian or other person designated to request documents from ASTIA.

When U. S. Government drawings, specifications, or other data are used for any purpose other than a definitely related government procurement operation, the government thereby incurs no responsibility nor any obligation whatsoever; and the fact that the government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

FOREWORD

This report was prepared in the Bionucleonics Department* and the Veterinary Services Branch† by the following personnel:

GEORGE S. MELVILLE, Jr., Captain, USAF*
GEORGE W. HARRISON, Jr., B. A.*
THOMAS P. LEFFINGWELL, M. A.*
WALTER H. WHITCOMB, Captain, USAF, MC*
ROBERT J. YOUNG, Major, USAF, VCG

Best Available Copy

ABSTRACT

In this study, postirradiation symptomatic therapy of the radiation syndrome has been utilized to provide significant extension of survival time, compared to irradiated controls, of *Macaca mulatta* primates irradiated to a total dose of 900 r. Further, the therapeutic regimen has been successfully combined with chemical radioprotectants to enhance survival time in a third group of animals. This combined treatment is more effective than the therapy alone. The overall clinical condition of these animals is far superior to that of the untreated irradiated animals. Pathologic studies of the deceased animals indicate that the two major causes of death were lung vascular failure and severe lymphoid atrophy. The protective chemical treatment is in itself a combination of different mechanisms of radioprotection, routes of administration, and sites and rates of absorption of the drugs.

This technical document report has been reviewed and is approved.

Robert B. Payne
ROBERT B. PAYNE
Colonel, USAF, MSC
Chief, Operations Division

Best Available Copy

PROTECTION AGAINST IONIZING RADIATION

X-irradiated Monkeys Receiving Preirradiation Prophylaxis and Postirradiation Therapy

1. INTRODUCTION

In previous studies in this laboratory it has been shown that the radioprotection conferred by certain sulfhydryl-containing chemicals can be enhanced in rats, either additively or synergistically by other compounds (5). Similar studies have also been effected in monkeys, and the findings on the primate substantiate those found for the rodent (4).

At the present "state-of-the-art" of chemical radioprotection, it would seem that, although effective radiation dose reduction can be achieved, a supralethally irradiated animal will still sustain appreciable damage. Hence, if not all of the clinical sequelae of radiation sickness thus will be manifested. Clinical treatment of chemically protected animals therefore becomes essential if the dose-reducing advantages of the radioprotective chemicals are to be optimized.

This report details the first study accomplished at this laboratory in which radioprotective prophylaxis has been followed by medical treatment after the irradiation has been administered. Eight monkeys were given the best chemical treatment available in this laboratory (3, 4, 5), after which they received 900 r of x-rays $\approx$ 100% lethal within 45 days of this laboratory, and approximately that elsewhere (2). The same animals received medical treatment as suggested by clinical indices. Results indicate that the combination of chemicals significantly increased the life-span of

all survivors, the longest lived surviving at 618 days postexposure.

2. MATERIAL AND METHODS

The monkeys used were of the *Macaca mulatta* strain of rhesus monkey and ranged from 4.5 to 6.5 lb. The eight treated animals were chosen at random from a larger group of healthy animals. In this selection, no distinctions were made on the basis of sex; there were two females and six males. Ten other animals (four females and six males) were irradiated at 900 r as controls: four no-treatment controls, and six postirradiation therapy controls.

The whole-body x-irradiations were performed with a Picker x-ray machine at 200 kVp, 18 ma, with 1 mm. Al and 0.25 mm. Cu added filtration. The dose rate was 18 to 20 r/min.; the exposure cage was rotated at 15 r.p.m. S,2-aminoethylisothiuronium dibromide (AET) was synthesized and purified in this laboratory by the method of Stepien (7).

All protected animals received AET-dibromide (75 mg/kg. body weight) plus cysteine-HCl (225 mg/kg. body weight) intravenously, 60 minutes prior to irradiation; AET-dibromide (150 mg/kg. body weight) plus cysteine-HCl (150 mg/kg. body weight) orally, 15 minutes before irradiation, and Nembutal (8 to 10 mg./lb. body weight) intravenously, 15 minutes prior to irradiation.

Intravenous doses of AET and cysteine were prepared by weighing the appropriate amount of each into a common vessel, and neutralizing them with 2.5 Normal NaOH to a final pH of

This work was conducted at the Radiation Research Laboratory of the University of Texas, and the United States Air Force, Austin, Tex.

7.2 to 7.4. Samples were diluted to 10 ml. with distilled water and administered 60 minutes before irradiation.

Oral doses of AET and cysteine were prepared in a similar manner, neutralized together with 2.5 normal NaOH to a pH of 7.2 to 7.4, diluted to 8 to 10 ml. with 0.5 M phosphate buffer, and gavaged 15 minutes before irradiation.

Nembutal was administered intravenously 15 minutes before irradiation at a dose of 8 to 10 mg./lb. body weight. A minimum dose was used to achieve anesthesia, checking by the "eyelid-reflex" method. As a result, the entire calculated dose was sometimes not used.

Hematologic examinations were accomplished on blood drawn by femoral puncture;

the methods specified by Wintrobe (9) were used for counting and for other determinations.

Bacteriologic and parasitologic examinations were effected on blood and feces both before and after irradiation. Samples for parasitology were examined by the ether concentration method; stool bacteriologic samples were examined by the standard "three-media" technic and then by tetrathionate enrichment; blood bacteriologic samples were collected on 1-oz. agar slants using tryptose-glucose broth, and then plated by standard techniques. To aid in the use of antibiotics, positive blood cultures were tested for sensitivity to various drugs by using the paper disc method.

Temperatures were obtained rectally; in this laboratory, 102° F. is a normal mean value for this strain of monkey.

TABLE I
Survival of monkeys irradiated with 800 r of x-rays

Animal No.	Survival time (day)	Experimental treatment
Group I		
111C	9	None
134P	9	
71E	9	
197I	22	
Group II		
92E	11	Post-irradiation therapy as indicated by individual symptoms
91E	11	
71F	12	
31E	13	
78E	15	
111P	22	
Group III		
66E	14	All animals received the following treatments (per kilogram body weight): 60 minutes pre-irradiation: Intravenous injection of AET-410 (76 mg.) plus Cysteine-410 (725 mg.) in neutralized aqueous solution
98E	21	
60E	22	
55P	22	
31E	22	
122E	31	15 minutes pre-irradiation: AET-410 (160 mg.) plus Cysteine-410 (150 mg.) administered orally alone. Irradiation (840 mg.) administered intravenously
99E	250	
48E	313	
		Post-irradiation therapy as indicated by individual symptoms

Water intake was obtained by calculating the amount consumed from a 500-ml. bottle of water given to each animal daily. Food consumption (in calories) was calculated by estimating the unconsumed portion of the amount given approximately 16 hours after feeding.

The survival time, calculated in days, was used in comparing the treated animals with the irradiated-therapy controls, and separately with the irradiated controls that received no treatment. The Mann-Whitney "U" Test was used, as expounded by Segal (8). Mortality data were arranged in contingency tables and

the probabilities were calculated by Fisher's Exact Method at the 30-day point.

3. RESULTS

Table I summarizes the longevity of the eight animals that were treated before and after irradiation (group III); control animals that were given therapy after irradiation (group II); and the four irradiated control animals that received no treatment (group I). Mean survival time for group I was 10 days; group II, 23 days; group III, 135 days.

Figure 1 shows weight and temperature changes for the first 30-day period postirradiation.




FIGURE 1

Postirradiation changes in body weight and temperature for groups II and III.

tion. These values are means for the animals which were alive when the sample was taken; weights have been presented as percentages of the baseline values before irradiation which, in turn, have been normalized to the normal value for the rhesus monkey in this colony. The animals pretreated with the chemical protectants (group III) maintain their weight better than those that received supportive treatment only (group II).

Variations in temperature are less dramatic; however, animals in group III also maintain their body temperature better during the early and late stages of the 10-day period, and there is less fluctuation than in group II. Figure 2 is a histogram which presents four peripheral blood parameters for groups II and III. The values are means for the animals alive at the time of the sampling. There are very few differences in the two groups. The




FIGURE 2

Program showing percentage changes in platelets, hemoglobin, and erythrocytes for groups II and III.

TABLE II

Statistical probabilities for the survival of monkeys

	Fisher's Exact Test (Number dead or alive)	Mann-Whitney "U" Test (days until death)
Group I* vs. Group II†	.500	.033 > P > .100
Group I* vs. Group III‡	.348	.002
Group II† vs. Group III‡	.200	.028

*Irradiated control animals.
†Irradiated animals receiving supportive treatment.
‡Irradiated animals receiving protective treatment.

white blood cell count is higher for group II, and, although to less extent, platelets and reticulocytes are also higher. In group III, hemoglobins are somewhat higher during the last week.

Table II shows the results obtained by applying Fisher's Exact Test and the Mann-Whitney "U" Test to these data. None of the mortality data are considered significant (requirements $P < .05$); however, there is significant improvement in survival times in all cases.

Table III summarizes the remainder of the clinical history of group II before and after irradiation. The animals have been listed in order of increasing longevity. The numbers in parentheses indicate the first day on which cultures were positive, and the days on which drugs were administered. It will be noted that animals receiving the most treatment lived the longest. Clinically, however, these animals showed the most symptoms since symptoms were the basis for therapy.

As the general condition of the animals of group I was very poor, they were delineated quite easily from the treated groups at the end of the first week. Symptoms included

TABLE III
Clinical summary for group I⁶

Animal No.	Preirradiation				Postirradiation				Therapy
	Ova and parasites	Enteric pathogens	Pathogens	Hematology	Ova and parasites	Enteric pathogens	Stool	Blood	
92E	Negative	Negative	Negative	Normal	Negative	<i>Saligella</i> (8) *	Negative	<i>Staphylococcus aureus</i> (8)	Blind infection (10)†
93E	Negative	Negative	Negative	Normal	Negative	Negative	Negative	Negative	No change observed
71E	Negative	Negative	Negative	Normal	Negative	Negative	Negative	Negative	No change observed
84E	Negative	Negative	Negative	Normal	Negative	Negative	Negative	Enteric hemolytic streptococcus (11)	Aminosol and saline intravenously (12), Streocillin (12)
75E	Negative	Negative	Negative	Normal	Strongly positive (14)	Negative	Negative	Negative	Normal MBi and 5% dextrose intravenously (13), Streocillin (15)
86E	Negative	Negative	Negative	Normal	Strongly positive (22)	Negative	Negative	<i>Staphylococcus aureus</i> (9, 15), Beta hemolytic streptococcus (11), <i>Streptococcus faecalis</i> (12), <i>Streptococcus</i> (22)	Normal MBi and 5% dextrose intravenously (9, 16), Streptomycin (16-18), Aminosol plus, Monosol MB and 5% dextrose intravenously (17-18), Streocillin (18)

*Numbers in parentheses indicate date of examination in days after irradiation.

†All drugs given intramuscularly unless otherwise specified.

‡These letters are the initials of the person to whom the name of the animal was assigned.

Clinical summary for group III

Animal No.	Pre-irradiation			Post-irradiation			Therapy
	Stool	Enteric pathogens	Stool	Stool	Blood	Pathogens	
40E	Ova and parasites Negative	Negative	Ova and parasites Negative	Negative	Negative	<i>Micromonas</i> spp. (8)	Achromycin orally (9-11), Streocillin† (9-11), Achromycin (10-11), 5% dextrose and saline orally (10-11), Iodosp MB† and 5% dextrose intravenously (10), Aminogol and saline intravenously (11)
42E	Negative	Negative	Negative	Negative	Negative	Negative	Achromycin (13)
43E	Negative	Negative	Negative	Negative	Negative	Negative	Achromycin (14-15), Amino-plus, 5% dextrose and 5% dextrose intravenously (16), Iodosp MB, 10% dextrose and 5% dextrose intravenously (15, 16), Amino-plus and 5% dextrose in Ringer's solution intravenously (19)
55E	Negative	Negative	Negative	Negative	Negative	Negative	Gamman globulin (7-12), Bicillimycin (8-13), Chloromycetin (14-21), Bectal (15-21), blood transfusion (14)
83E	Negative	Negative	Negative	Negative	Negative	<i>Micromonas</i> spp. (14)	Achromycin (14-19)
125E	Negative	Negative	Negative	Negative	Negative	Negative	Bicillimycin (12-16), gentian violet orally (27-36), Entromycin (39-41, 62-69)
99E	Negative	Negative	Negative	Negative	Negative	<i>Micromonas</i> spp. (15)	Furozone (14-19)
48E	Negative	Negative	Negative	Negative	Negative	Negative	No drugs given

*Numbers in parentheses indicate days postirradiation that symptom was noted or drug administered.

†All drugs given intramuscularly unless otherwise indicated.

‡The letters are an integral part of the name of a class of Abbott parenteral fluids indicating clinical use.

acute anorexia, diarrhea, bloody diarrhea, dehydration, some epilation, and very low body temperature occurring just before death. At the end of the first week, essentially no white cells or platelets were detected in the peripheral blood. The extremely short survival time of the monkeys in group I makes it impossible to plot curves showing data comparable to that of the other groups.

Figure 3 shows the calorie and fluid intake of the animals expressed as the group mean percent of the amount offered. The numbers in parentheses represent the number of animals comprising the group at that time. These data indicate that failure to utilize available fluid is an extremely important factor in maintaining the normal fluid balance, and that the protective drugs do not appreciably alter the situation. Postirradiation anorexia was seen in both groups, but was somewhat less severe in

group III and appeared some seven days later than in group II.

Tables V, VI, and VII describe the pathologic findings for groups I, II, and III, respectively. Bone marrow failure and atrophy of lymphoid tissue are consistent findings in all groups. Animal 48E (group III), which lived 618 days after irradiation, actually showed a slightly hypercellular bone marrow with numerous mitotic figures. It is interesting to observe the occurrence of meningitis (99E, table VII); this finding has been noted in several animals in other phases of the research (6).

2. DISCUSSION

This is the first experiment at this laboratory in which any protected animal has survived as long as 30 days after being given




FIGURE 3

Postirradiation changes in food and water consumption for groups II and III.

TABLE V

Pathologic summary for group I

Animal No.	Gross findings	Microscopic findings
115C	Petechiae of skin, stomach. Superficial erosion and hemorrhage, cecum. Focal hemorrhage, colon.	Atrophy, bone marrow lymphoid tissue. Atrophy, slight, intestinal epithelium.
134F	Petechiae of skin. Focal hemorrhage of subarachnoid space, cerebral cortex, lung. Hemorrhagic ulcers, colon.	Atrophy, bone marrow and lymphoid tissue. Slight atypia of colonic mucosa.
14E	Ulceration and hemorrhage, cecum, descending colon and rectum. Petechial hemorrhage, mucosa stomach and urinary bladder.	Atrophy, bone marrow and lymphoid tissue. Fatty metamorphosis, slight, liver.
13H	Petechial hemorrhages of skin, gastric intestinal mucosa, serous surfaces, lungs. Ulceration, mild, colonic mucosa.	Atrophy, bone marrow and lymphoid tissue. Bacterial colonization, kidney, adrenal, and lung.

TABLE VI

Pathologic findings for group II

Animal No.	Gross findings	Microscopic findings
71E	Petechial hemorrhages of skin, serous surfaces, epicardium, stomach, and small intestine. Subarachnoid hemorrhage, focal. Ulceration and hemorrhage, transverse colon.	Hemorrhage and ulceration of colonic mucosa with pseudomembrane formation. Atrophy of bone marrow and lymphoid tissue. Massive hemorrhage and edema of lungs.
78E	Petechial hemorrhages of skin, serous surfaces, epicardium, liver, stomach, colon, urinary bladder. Ulceration and hemorrhage, ileum. Ulceration and hemorrhage, cecum.	Atrophy, bone marrow, with early regeneration. Atrophy, lymphoid tissue.
84E	Petechial hemorrhages of skin, gums, serous surfaces, epicardium, stomach, small intestine, and colon. Hemorrhage and edema, tissues of pelvis. Multiple small hemorrhagic ulcers, colon. Hemorrhage and ulceration, rectum. Severe ulcers, hemorrhagic, skin.	Atrophy, bone marrow and lymphoid tissue. Hemorrhagic ulcers, colon, and skin. Submucosal hemorrhage, focal, colon. Edema, lungs.
92E	Widespread petechial and focal hemorrhage. Focal ulceration of stomach mucosa. Ulcers, lips. Congestion, lungs.	Atrophy, bone marrow and lymphoid tissue. Mucosal necrosis, focal, stomach.
93E	Generalized petechial hemorrhage. Hemorrhage and thickening of colonic mucosa. Subarachnoid hemorrhage, right arachnoid hemorrhage, right frontal lobe, minimal.	Atrophy, bone marrow and lymphoid tissue. Necrosis and hemorrhage, focal, colon.
114E	Softening of right maxilla. Purulent material in maxillary sinus.	Reduced cellularity of bone marrow. Atrophy, lymphoid tissue. Osteomyelitis, maxilla, acute and chronic.

TABLE VII
Pathologic findings for group III

Animal No.	Gross findings	Microscopic findings
55E	Four large perforated ulcers in colon and rectum. Small white nodules throughout lungs. Calcified nodules in spleen. Petechiae of stomach and bladder.	Focal fibrosis and calcification of spleen and lungs. Acute purulent meningitis, cerebellum and cerebrum. Penetrating ulcers of colon. Atrophy, lymphoid tissue. Hypoplasia, myeloid series, bone marrow.
66E	Widespread petechial and focal hemorrhage. Distention, stomach and small intestine. Hemorrhagic colitis, cecum. Ulcers, 11p.	Ulceration and hemorrhage of colonic mucosa with pseudomembrane. Atrophy, bone marrow and lymphoid tissue. Widespread bacterial colonization.
80E	Subcutaneous hemorrhage and edema, face, and neck. Generalized petechial hemorrhage. Subarachnoid hemorrhage, focal. Hemorrhage and edema, lungs.	Atrophy, lymphoid tissue. Hemorrhage, edema, and pneumonia, lungs. Regeneration, bone marrow.
82E	Edema and congestion, colon, slight.	Crypt abscesses, colon. Atrophy, lymphoid tissue. Hypocellularity of bone marrow.
98E	Hemorrhage, petechial and focal generalized. Hemorrhage, esophagus and mediastinum. Multiple small white nodules, liver. Hemorrhage and edema, skeletal, colon.	Atrophy bone marrow and lymphoid tissue. Focal necrosis, liver. Bacterial colonization, generalized. Hemorrhage and edema, submucosal, colon. Focal hemorrhage and pneumonia, lungs.
99E	Hemorrhage, petechial, skin, stomach, rectum, kidneys. Congestion, spleen.	Focal arteriolar and tubular necrosis, kidneys. Focal interstitial hemorrhage, kidneys. Thrombosis, focal, glomerular capillaries. Atrophy, lymphoid tissue. Meningitis, acute.
123E	Petechial hemorrhage, heart, small intestine, colon. Hemorrhage, focal, lungs. Multiple small abscesses, lungs.	Mild focal inflammation, colon. Extensive areas of pulmonary edema, hemorrhage and inflammation with abscess formation. Abscess, myocardium.
124E	Congestion, lungs. Mucosal ulceration with pseudomembrane formation, ascending colon.	Right hyperplasia, bone marrow. Atrophy, lymphoid tissue. Diffuse inflammatory infiltration, lungs. Ulceration and purulent exudate, colon. Hyperplasia, focal, testes.

900 r of x-rays; it is also the first time a symptomatically treated animal has survived more than 30 days at this level of irradiation.

The chemical treatment used for radioprotection is more extensive than other treatment previously reported in primates (1, 4). We combined different mechanisms of protection, routes of administration, and sites and rates of absorption. For example, (1) the in-

travenous dose affords a high blood level of a good radical sump (AKT or a homolog) and an additional compound (cysteine) which may be a radical sump and may also participate in normal oxidative metabolism; (2) an oral dose of the same compounds provides direct physical contact and presumably absorption in the gastrointestinal tract, and allows the total concentration of the drugs to be increased without noticeably increasing the toxicity; and (3) the

use of pentobarbital sodium introduces a drug which decreases respiration (in terms of relative O_2 concentrations), lowers the overall metabolism rate, creates some tissue hypoxia, and potentiates the effect of AET (5).

The actual chemical species present in a homogeneous aqueous mixture of AET and cysteine is yet to be determined. Preliminary work shows that the protective effect of this mixture depends on the concentrations of the two compounds; it also indicates that when the two compounds are mixed in water before treatment, they are more effective than when they are given to the same animal in separate aqueous solutions. The product may be a mixed disulfide or a sulfhydryl compound of relatively high molecular weight. The problem is being investigated by paper chromatographic methods.

There seems to be no question that chemical protection and symptomatic postirradiation therapy can be advantageously combined to ameliorate radiation injury. The chemical prophylaxis very probably decreases radiation damage to the gastrointestinal tract. The fact that it does not appear to protect the lymphoid tissue or the bone marrow confirms the findings already reported in some 80 other chemically protected monkeys that were given lethal or supralethal doses of x-rays (6). These earlier results are further typified by the histopathologic findings that demonstrate bone marrow recovery but lymphatic tissue failure, as in the case of 48E.

The classical symptoms of radiation death— anorexia, diarrhea, dehydration, epilation, and weight loss—are found to a lesser extent, or are delayed considerably, in the therapy animals and in the protected-therapy animals.

REFERENCES

1. Crouch, B. G., and R. R. Overman. Chemical protection against x-irradiation death in primates: A preliminary report. *Science* 125:1092-1098 (1957).
2. Henschke, U. K., and J. L. Morton. Mortality of rhesus monkeys after single total body irradiation. *Amer. J. Roentgenol.* 77:899-909 (1957).
3. Melville, G. S., Jr., and T. P. Leffingwell. Radioprotection of female rats with AET. USAF School of Aerospace Medicine Report 60-40, May 1960.
4. Melville, G. S., Jr., R. E. Benson, T. P. Leffingwell, and G. W. Harrison, Jr. Radioprotection in primates: A preliminary report. USAF School of Aerospace Medicine Report 61-3, Jan. 1961.
5. Melville, G. S., Jr., and T. P. Leffingwell. Potentiation by pentobarbital of the protective effect of AET against gamma rays. USAF School of Aerospace Medicine Report 61-87, Oct. 1961.
6. Pitcock, J. A., and G. S. Melville, Jr. Subacute radiation death in chemically protected monkeys. USAF School of Aerospace Medicine Report 61-102, Sept. 1961.
7. Shapira, R., D. G. Doherty, and W. T. Burnett, Jr. Chemical protection against ionizing radiation: III. Mercaptoalkylguanadines and related isothiuronium compounds with protective activity. *Radiat. Res.* 7:22-34 (1957).
8. Siegel, S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956.
9. Wintrobe, M. M. Clinical hematology, 4th ed. Philadelphia: Lea and Febiger, 1958.

USAF School of Aerospace Medicine, Brooks AF Base, Tex.

SAM-TDR-62-103. PROTECTION AGAINST IONIZING RADIATION: X-IRRADIATED MONKEYS RECEIVING PREIRRADIATION PROPHYLAXIS AND POSTIRRADIATION THERAPY. Dec. 62. 10 pp. incl. illus., tables, 9 refs.

Unclassified Report.

In this study, postirradiation symptomatic therapy of the radiation syndrome has been utilized to provide significant extension of survival time, compared to irradiated controls, of *Macaca mulatta* primates x-irradiated to a total dose of 900 r. Further, the

1. Radiobiology
2. Radioprotection

I. AFSC Project 7757,
Task 67007

II. Melville, G. S., Jr.,
Harrison, G. W., Jr.,
Leffingwell, T. P.,
et al.

III. In ASTIA collection

USAF School of Aerospace Medicine, Brooks AF Base, Tex.

SAM-TDR-62-103. PROTECTION AGAINST IONIZING RADIATION: X-IRRADIATED MONKEYS RECEIVING PREIRRADIATION PROPHYLAXIS AND POSTIRRADIATION THERAPY. Dec. 62. 10 pp. incl. illus., tables, 9 refs.

Unclassified Report.

In this study postirradiation symptomatic therapy of the radiation syndrome has been utilized to provide significant extension of survival time, compared to irradiated controls, of *Macaca mulatta* primates x-irradiated to a total dose of 900 r. Further, the

1. Radiobiology
2. Radioprotection

I. AFSC Project 7757,
Task 67007

II. Melville, G. S., Jr.,
Harrison, G. W., Jr.,
Leffingwell, T. P.,
et al.

III. In ASTIA collection

USAF School of Aerospace Medicine, Brooks AF Base, Tex.

SAM-TDR-62-103. PROTECTION AGAINST IONIZING RADIATION: X-IRRADIATED MONKEYS RECEIVING PREIRRADIATION PROPHYLAXIS AND POSTIRRADIATION THERAPY. Dec. 62. 10 pp. incl. illus., tables, 9 refs.

Unclassified Report.

In this study, postirradiation symptomatic therapy of the radiation syndrome has been utilized to provide significant extension of survival time, compared to irradiated controls, of *Macaca mulatta* primates x-irradiated to a total dose of 900 r. Further, the

1. Radiobiology
2. Radioprotection

I. AFSC Project 7757,
Task 67007

II. Melville, G. S., Jr.,
Harrison, G. W., Jr.,
Leffingwell, T. P.,
et al.

III. In ASTIA collection

USAF School of Aerospace Medicine, Brooks AF Base, Tex.

SAM-TDR-62-103. PROTECTION AGAINST IONIZING RADIATION: X-IRRADIATED MONKEYS RECEIVING PREIRRADIATION PROPHYLAXIS AND POSTIRRADIATION THERAPY. Dec. 62. 10 pp. incl. illus., tables, 9 refs.

Unclassified Report.

In this study, postirradiation symptomatic therapy of the radiation syndrome has been utilized to provide significant extension of survival time, compared to irradiated controls, of *Macaca mulatta* primates x-irradiated to a total dose of 900 r. Further, the

1. Radiobiology
2. Radioprotection

I. AFSC Project 7757,
Task 67007

II. Melville, G. S., Jr.,
Harrison, G. W., Jr.,
Leffingwell, T. P.,
et al.

III. In ASTIA collection

therapeutic regimen has been successfully combined with chemical radioprotectants to enhance survival time in a third group of animals. This combined treatment is more effective than the therapy alone. The overall clinical condition of these animals is far superior to that of the untreated irradiated animals. Pathologic studies of the deceased animals indicate that the two major causes of death were bone marrow failure and severe lymphoid atrophy. The protective chemical treatment is in itself a combination of different mechanisms of radioprotection, routes of administration, and sites and rates of absorption of the drugs.

therapeutic regimen has been successfully combined with chemical radioprotectants to enhance survival time in a third group of animals. This combined treatment is more effective than the therapy alone. The overall clinical condition of these animals is far superior to that of the untreated irradiated animals. Pathologic studies of the deceased animals indicate that the two major causes of death were bone marrow failure and severe lymphoid atrophy. The protective chemical treatment is in itself a combination of different mechanisms of radioprotection, routes of administration, and sites and rates of absorption of the drugs.

therapeutic regimen has been successfully combined with chemical radioprotectants to enhance survival time in a third group of animals. This combined treatment is more effective than the therapy alone. The overall clinical condition of these animals is far superior to that of the untreated irradiated animals. Pathologic studies of the deceased animals indicate that the two major causes of death were bone marrow failure and severe lymphoid atrophy. The protective chemical treatment is in itself a combination of different mechanisms of radioprotection, routes of administration, and sites and rates of absorption of the drugs.

therapeutic regimen has been successfully combined with chemical radioprotectants to enhance survival time in a third group of animals. This combined treatment is more effective than the therapy alone. The overall clinical condition of these animals is far superior to that of the untreated irradiated animals. Pathologic studies of the deceased animals indicate that the two major causes of death were bone marrow failure and severe lymphoid atrophy. The protective chemical treatment is in itself a combination of different mechanisms of radioprotection, routes of administration, and sites and rates of absorption of the drugs.